U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07069335) titled 'A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer' on July 07.
Brief Summary: This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.
Study Start Date: June 17
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Intervention:
DRUG: Olaparib 150 MG
Subjects receive 600 mg per day, two tablets BID (total 4...